Techno Medica (6678) Q1 2026 earnings summary

Executive summary

• Revenue for Q1 FY2026 was ¥1,757 million, a 12.1% decrease year-over-year due to fewer large-scale domestic sales projects.

• Operating loss was ¥2.8 million, compared to an operating profit of ¥250.6 million in the prior year.

• Net income dropped 90.5% year-over-year to ¥16.5 million, impacted by lower sales and increased SG&A expenses.

• Overseas sales ratio increased by 0.4 points to 17.2% of total sales.

Financial highlights

• Gross profit was ¥811.8 million, down 19.5% year-over-year.

• SG&A expenses rose 7.4% to ¥814.7 million, driven by higher R&D and personnel costs.

• Ordinary profit was ¥23.5 million, a 90.8% decrease year-over-year.

• EPS for Q1 was ¥2.38, down from ¥25.10 in the prior year.

Outlook and guidance

• No changes to previously announced forecasts: full-year revenue expected at ¥10,600 million (+7.0% YoY), operating profit ¥1,480 million (+13.8% YoY), net income ¥1,100 million (+9.5% YoY).

• Interim dividend forecast unchanged at ¥68 per share.